Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review

Author： Lavecchia Antonio Di Giovanni Carmen Novellino Ettore

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.20, Iss.3, 2010-03, pp. : 405-425

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synthetic Small Molecule Cdc25 Phosphatases Inhibitors

Current Medicinal Chemistry, Vol. 15, Iss. 6, 2008-03 ,pp. : 573-580

Bentham Science Publishers

Access to resources Recommend Favorite

Topoisomerase inhibitors as anticancer agents: a patent update

By Khadka Daulat B Cho Won-Jea

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1033-1056

Informa Healthcare

Access to resources Recommend Favorite

Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents

Drug Design Reviews - Online, Vol. 1, Iss. 2, 2004-04 ,pp. : 123-132

Bentham Science Publishers

Access to resources Recommend Favorite

CDC25 Phosphatase Inhibitors: An Update

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 1, 2012-01 ,pp. : 62-73

Bentham Science Publishers

Access to resources Recommend Favorite

Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010)

By Marzaro Giovanni Guiotto Adriano Chilin Adriana

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 3, 2012-03 ,pp. : 223-252

Informa Healthcare

Access to resources Recommend Favorite